Abstract
Background
Many studies have indicated the adequate use of lipid-lowering drugs (LLDs) as a factor in reducing the risk of cardiovascular disease. However, in clinical practice, a very high percentage of patients are not adequately treated.
Objective
To analyze the management of hypercholesterolemia in a non-experimental setting and to estimate the factors associated with poor adherence to treatment.
Methods
A longitudinal study was performed using clinical and demographic data recorded in the General Practitioners’ database. The sample included all patients, aged 30 years or over, with total blood cholesterol measured between 1 January and 31 December 2000. Utilization of LLDs was defined as the standardized daily dose of the drugs purchased during the 12 months preceding the cholesterol measurement.
Results
The study included 4764 patients (mean age 59.4±14.1 years, 40.7% males). Of the subjects with a total cholesterol higher than a 6.5 mmol/l, approximately 17% were treated with LLDs. About 39% of the patients with previous atherosclerotic diseases were taking statins. Analysis of patients taking LLDs showed that 40.6% of subjects took less than half of the defined daily dose. Factors associated with poor adherence to treatment were: absence of previous atherosclerotic diseases, absence of concomitant diseases, and smoking. A total cholesterol of less than 5 mmol/l was achieved in 19.9% of patients.
Conclusions
Analyzing the data contained in the general medicine database made it possible to evaluate the use of LLDs in clinical practice and to establish the need to pay greater attention to achieving the objective set by the treatment.
References
Chen Z, Peto R, Collins R et al (1991) Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 303:276–282
Jacobs D, Blackburn H, Higgings M et al (1992) for participants in the conference on low cholesterol: mortality association. Report of the conference on low cholesterol: mortality association. Circulation 86:1046–1060
Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) For the multiple risk factor intervention trial research group. Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diab Care 16:434–444
Pignone M, Phillips C, Mulrow C (2000) Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 321:983–986
Hebert PR, Gaziano M, Chan KS, Hennekens CH (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 278:313–321
Gordon DJ (2000) Cholesterol lowering reduces mortality: the statins. In: Grundy SM (ed) Cholesterol-lowering therapy: evaluation of clinical trial evidence. Marcel Dekker, New York, pp 299–311
Degli Esposti L, Di Martino M, Saragoni S et al (2004) Pharmacoutilization of statin therapy after acute myocardial infarction. A real practice analysis based on administrative data. Ital Heart J 5(2):120–126
Jackevicius CA, Mamdani M, Tu JV (2002) Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA288:462–467
Benner JS, Glynn RJ, Mogun H et al (2002) Long-term persistence in use of statin therapy in elderly patients. JAMA 288:455–461
EUROASPIRE (1997) A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European action on secondary prevention through intervention to reduce events. Eur Heart J 18(10):1569–82
EUROASPIRE (2001) Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22(7):554–72
Andrade SE, Walker AM, Gottlieb LK et al (1995) Discontinuation of antihyperlipidemic drugs. N Engl J Med 332:1125–31
Walley T, Folino-Gallo P, Schwabe U et al (2004) Variations and increase in use of statins across Europe: data from administrative databases. BMJ 328:385–6
Larsen J, Vaccheri A, Andersen M et al (2000) Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. Br J Clin Pharmacol 49:463–471
Degli Esposti E et al (1999) The PANDORA project: results of the pilot study. Am J Hypertens 12:790–796
Prevention of coronary heart disease in clinical practice (1998) Recommendations of the second joint task force of European and other society on coronary prevention. Eur Heart J 19:1434–1503
Guidelines for ATC classification and DDD assignment, 5th edn (2002) WHO Collaborating Centre for Drug Statistics Methodology, Oslo
Abookire SA, Karson AS, Fiskio J, Bates DW (2001) Use and monitoring of statin lipid lowering drugs compared with guidelines. Arch Intern Med 161:53–58
Scandinavian Simvastatin Survival Study Group (1994) Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease. The Scandinavian simvastatin survival study. Lancet 344:1383–1389
Sacks FM, Pfeffer MA, Moye LA et al (1996) The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (CARE) investigators. N Engl J Med 335:1001–9
The long term intervention with pravastatin in ischemic disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349–57
MRC/BHF (2002) Heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (1997) The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157:2413–2446
Wilson P, D’Agostino R, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847
Abraha I, Montedori A, Stracci F et al (2003) Statin compliance in the Umbrian population. Eur J Clin Pharmacol 59:659–61
Einarson T, Bergman U, Wiholm BE (1997) Principles and practice of pharmacoepidemiology. In: Speight T, Holford N (eds) Drug treatment, 4th edn. Adis International Ltd, Auckland, pp 371–392
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Di Martino, M., Degli Esposti, L., Ruffo, P. et al. Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy. Eur J Clin Pharmacol 61, 225–230 (2005). https://doi.org/10.1007/s00228-005-0911-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-005-0911-z